Biosergen

Biosergen FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Biosergen (BIOSGN.ST) as of Oct 18, 2026 is 90.19 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 86.64 % — a change of 4.09% (higher).

FCF Conversion

90.19 %

YoY

4.09%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Biosergen is 2025 90.19 % . FCF Conversion Rate (FCF/EBITDA) of Biosergen was 2024 86.64 % . It decreases by 4.09% higher compared to the previous year.

The Biosergen FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
42.70 SEK
Jan 1, 2020
63.47 SEK
Jan 1, 2021
109.23 SEK
Jan 1, 2022
86.47 SEK
Jan 1, 2023
120.59 SEK
Jan 1, 2024
86.64 SEK
Jan 1, 2025
90.19 SEK
The Biosergen FCF Conversion history
YEARFCF ConversionYoY
90.19 %+4.09%
86.64 %-28.15%
120.59 %+39.46%
86.47 %-20.84%
109.23 %+72.10%
63.47 %+48.64%
42.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Biosergen Stock analysis

What does Biosergen do? Biosergen AB is a biopharmaceutical company headquartered in Solna, Sweden. The company went public on June 24, 2021, with its ticker symbol BIOSGN.ST and ISIN SE0026821852. Biosergen AB conducts biopharmaceutical research and development through its subsidiary Biosergen AS, utilizing laboratory facilities in Trondheim, Norway, and other global locations. The company is focused on developing BSG005, an antifungal drug that has shown safety and potency benefits compared to existing treatments. BSG005 is designed to address invasive fungal infections affecting immune-compromised patients, including those with AIDS, cancer, or who have undergone transplants. At equivalent doses, BSG005 has demonstrated a three- to fourfold higher potency against targeted fungal strains than current standard treatments, while avoiding the kidney toxicity associated with other drugs in its class. Biosergen AB operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is biosergen.net, providing further information about its research and development activities. The firm's primary focus remains on advancing BSG005 through clinical development, targeting a significant unmet medical need in the treatment of fungal infections among vulnerable patient populations. Biosergen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biosergen stock

FCF Conversion Rate (FCF/EBITDA) of Biosergen is 90.19 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Biosergen changed from 86.64 % to 90.19 %, representing a 4.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Biosergen since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Biosergen with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Biosergen

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Biosergen